Text Size

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This study has been terminated.
(Did not meet accrual goals.)
Sponsor:
Collaborator:
Genentech
Information provided by:
University of Connecticut Health Center
ClinicalTrials.gov Identifier:
NCT00408070
First received: December 5, 2006
Last updated: November 16, 2010
Last verified: November 2010
History of Changes
Results First Received: October 14, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Stage 3 Cancer
Stage 4 Cancer
Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

  Participant Flow
  Show Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Bevacizumab Plus Carboplatin and Paclitaxel This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.Cycle one - Paclitaxel 175 mg/m2 iv; Carboplatin AUC 6 iv; Cycle two through six - Paclitaxel 175 mg/m2 iv; Carboplatin AUC 6 iv; Avastin 15 mg/kg IV Repeat cycle every 21 days, total of 6 cycles

Baseline Measures
    Bevacizumab Plus Carboplatin and Paclitaxel  
Number of Participants  
[units: participants]
 		  5  
Age  
[units: participants]
 		 
<=18 years     0  
Between 18 and 65 years     2  
>=65 years     3  
Age  
[units: years]
Mean ± Standard Deviation 		  62  ± 11.20  
Gender  
[units: participants]
 		 
Female     5  
Male     0  
Region of Enrollment  
[units: participants]
 		 
United States     5  



  Outcome Measures

1.  Primary:   Progression Free Survival Rate at 9 Months   [ Time Frame: 9 months ]
  Show Outcome Measure 1

2.  Secondary:   Response to Treatment (Clinical/Pathological)   [ Time Frame: not assessed; study terminated early ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

3.  Secondary:   Rate of Decline of CA-125   [ Time Frame: not assessed; study terminated early ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   To Determine the Degree and Type of Toxicity of This Combined Regimen   [ Time Frame: weekly ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Determine Tolerability to 12 Months (q 3 Weeks) of Bevacizumab Maintenance Therapy   [ Time Frame: 12 months ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This trial ended early after enrolling only 5 of 100 patients. Due to the small enrollment number and incomplete data set, no data analyses were performed.  


Results Point of Contact:  
Name/Title: Paige Dunion
Organization: UCHC
phone: 860-679-6571
e-mail: pdunion@uchc.edu


No publications provided


Responsible Party: Carolyn Runowicz, MD, Univ. of CT Health Center
ClinicalTrials.gov Identifier: NCT00408070     History of Changes
Other Study ID Numbers: AVF 3696s, IRB 06-337-1
Study First Received: December 5, 2006
Results First Received: October 14, 2010
Last Updated: November 16, 2010
Health Authority: United States: Food and Drug Administration